Subeka Abraham Gnanadass1, Yogamaya Divakar Prabhu1, Abilash Valsala Gopalakrishnan2. 1. Department of Biomedical Sciences, School of BioSciences and Technology, Vellore Institute of Technology, Vellore, 632014, Tamil Nadu, India. 2. Department of Biomedical Sciences, School of BioSciences and Technology, Vellore Institute of Technology, Vellore, 632014, Tamil Nadu, India. abilash.vg@vit.ac.in.
Abstract
BACKGROUND: Polycystic ovarian syndrome (PCOS) is the most prevalent metabolic disorder in reproductive-age women. It is indeed a multifactorial condition evidenced by ovarian dysfunction, hyperandrogenaemia, infertility, hormonal imbalance and chronic anovulation. Experimental evidence infers that PCOS women are prone to cardiovascular problems and insulin resistance. PURPOSE: To furnish the details about the association of inflammatory markers in PCOS. DESIGN: An extensive literature search on PubMed, science direct and google scholar has been performed for articles about PCOS and inflammation in PCOS. A comprehensive analysis using original articles, reviews, systemic and meta-analysis was conducted for better understanding the relationship between inflammatory cytokines and PCOS. RESULTS: The inflammatory markers perform a substantial part in managing the functions of the ovary. Any disturbances in their levels can lead to ovarian dysfunction. Inflammatory markers are associated with PCOS pathogenesis. The interplay between inflammatory cytokines in the PCOS ovary strongly implies that inflammation is one of the most potent risk factors of PCOS. CONCLUSION: Inflammatory markers have a significant role in regulating the ovary. This manuscript highlights the significance of metabolic and inflammatory markers with PCOS. Since PCOS is always considered as a metabolic disorder, researchers can also consider focusing on the relationship between the inflammatory markers in PCOS to establish a new treatment or management of the disease and to improve women's health.
BACKGROUND:Polycystic ovarian syndrome (PCOS) is the most prevalent metabolic disorder in reproductive-age women. It is indeed a multifactorial condition evidenced by ovarian dysfunction, hyperandrogenaemia, infertility, hormonal imbalance and chronic anovulation. Experimental evidence infers that PCOSwomen are prone to cardiovascular problems and insulin resistance. PURPOSE: To furnish the details about the association of inflammatory markers in PCOS. DESIGN: An extensive literature search on PubMed, science direct and google scholar has been performed for articles about PCOS and inflammation in PCOS. A comprehensive analysis using original articles, reviews, systemic and meta-analysis was conducted for better understanding the relationship between inflammatory cytokines and PCOS. RESULTS: The inflammatory markers perform a substantial part in managing the functions of the ovary. Any disturbances in their levels can lead to ovarian dysfunction. Inflammatory markers are associated with PCOS pathogenesis. The interplay between inflammatory cytokines in the PCOS ovary strongly implies that inflammation is one of the most potent risk factors of PCOS. CONCLUSION: Inflammatory markers have a significant role in regulating the ovary. This manuscript highlights the significance of metabolic and inflammatory markers with PCOS. Since PCOS is always considered as a metabolic disorder, researchers can also consider focusing on the relationship between the inflammatory markers in PCOS to establish a new treatment or management of the disease and to improve women's health.
Authors: Ricardo Azziz; Enrico Carmina; Didier Dewailly; Evanthia Diamanti-Kandarakis; Hector F Escobar-Morreale; Walter Futterweit; Onno E Janssen; Richard S Legro; Robert J Norman; Ann E Taylor; Selma F Witchel Journal: J Clin Endocrinol Metab Date: 2006-08-29 Impact factor: 5.958
Authors: Erifili Hatziagelaki; Vasilios Pergialiotis; Julia M Kannenberg; Eftihios Trakakis; Anastasia Tsiavou; Daniel F Markgraf; Maren Carstensen-Kirberg; Giovanni Pacini; Michael Roden; George Dimitriadis; Christian Herder Journal: Exp Clin Endocrinol Diabetes Date: 2019-08-28 Impact factor: 2.949
Authors: Annemarie G M G J Mulders; Joop S E Laven; Marinus J C Eijkemans; Frank H de Jong; Axel P N Themmen; Bart C J M Fauser Journal: Hum Reprod Date: 2004-06-24 Impact factor: 6.918
Authors: Ricardo Azziz; Enrico Carmina; ZiJiang Chen; Andrea Dunaif; Joop S E Laven; Richard S Legro; Daria Lizneva; Barbara Natterson-Horowtiz; Helena J Teede; Bulent O Yildiz Journal: Nat Rev Dis Primers Date: 2016-08-11 Impact factor: 52.329
Authors: Richard S Legro; Silva A Arslanian; David A Ehrmann; Kathleen M Hoeger; M Hassan Murad; Renato Pasquali; Corrine K Welt Journal: J Clin Endocrinol Metab Date: 2013-10-22 Impact factor: 5.958
Authors: Helena J Teede; Marie L Misso; Michael F Costello; Anuja Dokras; Joop Laven; Lisa Moran; Terhi Piltonen; Robert J Norman Journal: Hum Reprod Date: 2018-09-01 Impact factor: 6.918